Abstract
Down syndrome (DS) is defined by the presence of a third copy of chromosome 21. Several comorbidities can be found in these patients, such as intellectual disability (ID), muscle weakness, hypotonia, congenital heart disease, and autoimmune diseases. The molecular mechanisms playing a role in the development of such comorbidities are still unclear. The regulation and expression of genes that map to chromosome 21 are dynamic and complex, so it is important to perform global gene expression studies with high statistical power to fully characterize the transcriptome in DS patients. This study was undertaken to evaluate mRNAs and lncRNA expression in patients with DS versus a matched cohort of healthy subjects. RNA sequencing was used to perform this transcriptome study. Differential expression analysis revealed 967 transcripts with padj ≤ 0.05. Among them, 447 transcripts were differentially expressed in patients with DS compared to controls. Particularly, 203 transcripts were down expressed (151 protein-coding mRNAs, 45 lncRNAs, 1 microRNA, 1 mitochondrial tRNA, 1 ribozyme, and 1 small nuclear RNA) and 244 were over expressed (210 protein-coding mRNAs and 34 lncRNAs). Interestingly, deregulated lncRNAs are involved in pathways that play a role in developmental disorders, neurological diseases, DNA replication and repair mechanisms, and cancer development in DS patients. In conclusion, these results suggest a role of lncRNAs in the phenotype of DS patients.
References
Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5:725–38.
Zhao J, Zhang Z, Ren S, Zong Y, Kong X. Co-expression network analysis of Down’s syndrome based on microarray data. Exp Ther Med. 2016;12:1503–8.
Shapiro BL. Whither down syndrome critical regions? Hum Genet. 1997;99:421–3.
Li CM, Guo M, Salas M, Schupf N, Silverman W, Zigman WB, et al. Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med Genet. 2006;7:24.
Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:3.
Tang Y, Schapiro MB, Franz DN, Patterson BJ, Hickey FJ, Schorry EK, et al. Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down’s syndrome. Ann Neurol. 2004;56:808–14.
Altug-Teber O, Bonin M, Walter M, Mau-Holzmann UA, Dufke A, Stappert H, et al. Specific transcriptional changes in human fetuses with autosomal trisomies. Cytogenet Genome Res. 2007;119:171–84.
Salemi M, Longo GA, La Vignera S, Romano C, Condorelli RA, Romano C, et al. SPAG5 mRNA is over-expressed in peripheral blood leukocytes of patients with Down’s syndrome and cryptorchidism. Neurol Sci. 2013;34:549–51.
Birchler JA, Bhadra U, Bhadra MP, Auger DL. Dosage-dependent gene regulation in multicellular eukaryotes: implications for dosage compensation, aneuploid syndromes, and quantitative traits. Dev Biol. 2001;234:275–88.
Costa V, Angelini C, D’Apice L, Mutarelli M, Casamassimi A, Sommese L, et al. Massive-scale RNA-seq analysis of non ribosomal transcriptome in human trisomy 21. PLoS ONE. 2011;6:e18493.
Letourneau A, Santoni FA, Bonilla X, Sailani MR, Gonzalez D, Kind J, et al. Domains of genome-wide gene expression dysregulation in Down’s syndrome. Nature. 2014;508:345–50.
Lu J, Mccarter M, Lian G, Esposito G, Capoccia E, Delli-Bovi LC, et al. Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression. Hum Mol Genet. 2016;25:1714–27.
Mendioroz M, Do C, Jiang X, Liu C, Darbary HK, Lang CF, et al. Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models. Genome Biol. 2015;16:263.
Hamurcu Z, Demirtas H, Kumandas S. Flow cytometric comparison of RNA content in peripheral blood mononuclear cells of Down syndrome patients and control individuals. Cytometry B Clin Cytom. 2006;70:24–8.
Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014;46:618–23.
Kahmann NH, Rake AV. Altered nucleosome spacing associated with Down syndrome. Biochem Genet. 1993;31:207–14.
Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456:470–6.
Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol. 2011;22:366–76.
Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9:703–19.
Fenoglio C, Ridolfi E, Galimberti D, Scarpini E. An emerging role for long non-coding RNA dysregulation in neurological disorders. Int J Mol Sci. 2013;14:20427–42.
Salemi M, Marchese G, Cordella A, Cannarella R, Barone C, Salluzzo MG, et al. Long non-coding RNA GAS5 expression in patients with Down syndrome. Int J Med Sci. 2020;23:1315–9.
Love MI, Huber W, Anders S. Moderate estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–9.
Rao PT, Guddattu V, Solomon JM. Response abilities of children with Down syndrome and other intellectual developmental disorders. Exp Brain Res. 2017;235:1411–27.
Sobol M, Klar J, Laan L, Shahsavani M, Schuster J, Annerén G, et al. Transcriptome and proteome profiling of neural induced pluripotent stem cells from individuals with Down syndrome disclose dynamic dysregulations of key pathways and cellular functions. Mol Neurobiol. 2019;56:7113–27.
Pal U, Halder P, Ray A, Sarkar S, Datta S, Ghosh P, et al. The etiology of Down syndrome: maternal MCM9 polymorphisms increase risk of reduced recombination and nondisjunction of chromosome 21 during meiosis I within oocyte. PLoS Genet. 2021;17:e1009462.
Versacci P, Di Carlo D, Digilio MC, Marino B. Cardiovascular disease in Down syndrome. Curr Opin Pediatr. 2018;30:616–22.
Chin CJ, Khami MM, Husein M. A general review of the otolaryngologic manifestations of Down syndrome. Int J Pediatr Otorhinolaryngol. 2014;78:899–904.
Ross WT, Olsen M. Care of the adult patient with Down syndrome. South Med J. 2014;107:715–21.
Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regulation by the act of long non-coding RNA transcription. BMC Biol. 2013;11:59.
Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.
Lau E. Non-coding RNA: zooming in on LncRNA functions. Nat Rev Genet. 2014;15:3795.
Ruiz-Orera J, Messeguer X, Subirana JA, Alba MM. Long non-coding RNAs as a source of new peptides. Elife. 2014;3:e03523.
Moreau M, Benhaddou S, Dard R, Tolu S, Hamzé R, Vialard F, et al. Metabolic diseases and Down syndrome: how are they linked together? Biomedicines. 2021;22:221.
Sheridan R, Llerena J, Matkins S, Debenham P, Cawood A, Bobrow M. Fertility in a male with trisomy 21. J Med Genet. 1989;26:294–8.
Zühlke C, Thies U, Braulke I, Reis A, Schirren C. Down syndrome and male fertility: PCR derived fingerprinting, serological and andrological investigations. Clin Genet. 1994;46:324–6.
Pradhan M, Dalal A, Khan F, Agrawal S. Fertilty in men with Down syndrome: a case report. Fertil Steril. 2006;86:e1765.1-3.
Stearns PE, Droulard KE, Sahhar FH. Studies bearing on fertility of male and female mongoloids. Am J Ment Defic. 1961;65:37–41.
Schupf N, Zigman WB, Kapell D, Lee JH, Kline J, Levin B. Early menopause in women with Down’s syndrome. J Intellect Disabil Res. 1997;41:264–7.
Højager B, Peters H, Byskov AG, Faber M. Follicular development in ovaries of children with Down’s syndrome. Acta Paediatr Scand. 1978;67:637–43.
Rethoré MO, Rouëssé J, Satgé D. Cancer screening in adults with Down syndrome, a proposal. Eur J Med Genet. 2020;63:103783.
Liao W, Liu Y. Treatment outcomes in children with Acute lymphoblastic leukemia with versus without coexisting Down’s syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e21015.
Massara M, Bonavita O, Mantovani A, Locati M, Bonecchi R. Atypical chemokine receptors in cancer: friends or foes? J Leukoc Biol. 2016;99:927–33.
Zu G, Luo B, Yang Y, Tan Y, Tang T, Zhang Y, et al. Meta-analysis of the prognostic value of C-C chemokine receptor type 7 in patients with solid tumors. Cancer Manag Res. 2019;11:1881–92.
Salemi M, Cannarella R, Marchese G, Salluzzo MG, Ravo M, Barone C, et al. CCR3 gene overexpression in patients with Down syndrome. Mol Biol Rep. 2021;48:5335–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethical approval
The study was approved on June 03, 2017 by the local IRB (protocol n. 2017/05/31/CE-IRCCS-OASI/9).
Informed consent
All the study participants or their legal guardians signed informed consent to publish.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Salemi, M., Cannarella, R., Marchese, G. et al. Role of long non-coding RNAs in Down syndrome patients: a transcriptome analysis study. Human Cell 34, 1662–1670 (2021). https://doi.org/10.1007/s13577-021-00602-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13577-021-00602-3